NuPathe Inc.

NuPathe — Investor Presentation (October 2012)

19 slides from NuPathe's investor presentation, Oct 9, 2012

  1. Slide 1: Corporate Presentation October 9, 2012

    Corporate Presentation October 9, 2012 © 2012 NuPathe Inc. All rights reserved.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All remarks and information that are not historical facts are hereby identified as forward-looking statements for this purpose and include, a

  3. Slide 3: Zecuity: substantial near-term commercial opportunity

    ZecuityTM: substantial near-term commercial opportunity The first migraine patch Delivers sumatriptan, the #1 Rx migraine treatment Uniquely designed to overcome migraine-related nausea & vomiting Impacts half of all migraine sufferers PDUFA date Jan 17, 2013 Focused on gaining FDA approval, securin

  4. Slide 4: Zecuity – First and Only Migraine Patch

    Applied during migraine Rapidly delivers sumatriptan Bypasses GI tract Simple to use, single use Multiple application sites Strong intellectual property protection until April 2027 Zecuity – First and Only Migraine Patch

  5. Slide 5: Relieves Pain and Eliminates Nausea within One Hour

    Pivotal phase 3 efficacy data demonstrate: 39% more Zecuity patients had pain relief than placebo at 30 minutes* Sustained pain relief from 2 to 24 hours (P = 0.0015) Significant pain relief at 1 hour (P = 0.0135) Significant elimination of nausea at 1 hour (P = 0.0251) 71% nausea free at 1 hour, re

  6. Slide 6: Pivotal Phase Data Adverse Event Profile

    Pivotal Phase 3 Data Adverse Event Profile Application site events were typical of patches Majority were mild in intensity and transient Minimal incidence of adverse events known as triptan sensations Compared with product labeling for oral (>8%) and injection (>42%) Patch Placebo Application site p

  7. Slide 7: Comprehensive Safety Profile

    Extensive clinical program including more than 800 patients and 10,000 patch applications No drug-related serious adverse events Two 12-month, repeat use, open-label trials Very low incidence of triptan sensations (0.9%) No increased skin irritation with repeat or increased use 12-month completers u

  8. Slide 8: CRL issues and actions taken; NDA resubmitted

    Key CRL Issue Action Taken Skin events of concern Implemented device enhancement Prevents patch from activating when misapplied Packaging Usability Uniformity Containment Modified secondary packaging Usability study demonstrated all patients correctly applied patch during a migraine Additional data

  9. Slide 9: Triptans Dominate the Migraine Market

    31 million migraine sufferers Triptan market 94% of migraine prescriptions 97% of migraine sales Preferred class of migraine treatment 3 – 4 triptan trials before moving to different classes (e.g. opioids, DHE) Key challenge for triptans: circumventing pervasive migraine-related GI issues Injection

  10. Slide 10: Millions Remain Underserved

    Triptan Sensations Mimic a cardiovascular event >42% of injection patients > 8% of oral tab patients Millions Remain Underserved * Linked to a variety of factors, including gastroparesis. Gastroparesis Unreliable absorption Inconsistent Efficacy* >40% of treated patients Migraine-Related Nausea (MRN

  11. Slide 11: MRN Drives Tremendous Disease Burden

    Frequent nausea patients are less satisfied with their migraine medications Frequent nausea patients drive direct medical costs for migraine 5.4 times as many emergency/urgent care visits 8.2 times higher overnight hospital stay costs Presence of nausea predicts poor response to oral medications in

  12. Slide 12: Broad Formulary Coverage Expected

    Insurance is >90% commercial private pay Payors see value in a patch for migraine Acknowledge barrier of GI issues Recognize cost of poorly controlled migraine patients Accept patch as a unique solution Payors indicate broad formulary access Majority Tier 3; opportunities to contract for Tier 2 Non-

  13. Slide 13: Quantitative Research Confirms the Market Opportunity for the Patch

    Physicians rate the patch superior to oral, nasal, and injectable triptans for MRN patients on key attributes including: Ability to use early in a migraine attack despite GI issues Frequency of triptan sensations and overall tolerability Elimination of nausea at 1 and at 2 hours 77% of MRN patients

  14. Slide 14: Illustrative Market Opportunity

    1.5 million patients vomit with every migraine Branded injection pricing of $90/migraine 24 migraines per year Illustrative Market Opportunity (Only Patients Who Vomit with Every Migraine) 1.5 MM vomit during every attack

  15. Slide 15: Commercialization Strategy

    Secure commercial partnerships Patch is a versatile asset within a portfolio Migraine co-morbidity rates include: sleep disorders (52%), depression (44%), arthritis (26%), GERD (25%) Specialists (~10K) drive 1/3rd of triptan prescriptions Headache specialists and neurologists Primary care drives the

  16. Slide 16: Pipeline

    NP202: 90-day risperidone biodegradable implant to treat schizophrenia and bipolar disorder Designed to address significant patient non-compliance Continuous delivery reduces psychotic breaks and improves patient functionality1 Seeking global development & commercial partner NP201: 60-day ropinirole

  17. Slide 17: Financial

    Financing & cost containment measures expected to provide cash runway into 4Q13 $28 million financing expected to close in Oct/Nov Restructured $7.5 million of outstanding debt Headcount reduction and reduced spend on pipeline and commercialization activities Focused on achievement of key milestones

  18. Slide 18: Zecuity: substantial near-term commercial opportunity

    ZecuityTM: substantial near-term commercial opportunity The first migraine patch Delivers sumatriptan, the #1 Rx migraine treatment Uniquely designed to overcome migraine-related nausea & vomiting Impacts half of all migraine sufferers PDUFA date Jan 17, 2013 Focused on gaining FDA approval, securin

  19. Slide 19: References

    References Slide 9: 1. Lipton, R. Prevalence and Burden of Migraine in the United States: Data from the American Migraine Study II. Headache 2001 41:646-657. and US Census data (2010) 2. Data from IMS MAT June 2011. Triptans include Treximet. Analgesic combos = analgesic combos + Cambia 3. NuPathe p

NuPathe — Investor Presentation (October 2012) on 6ix